Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) Director Simon N. Pimstone sold 33,942 shares of the company’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $37.76, for a total transaction of $1,281,649.92. Following the transaction, the director now owns 58,058 shares in the company, valued at […]
Brown Advisory Inc. acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 12,911 shares of the biopharmaceutical company’s stock, valued at approximately $403,000. Other hedge […]